12/28/2025

Janusmed fosterpåverkan

Janusmed fosterpåverkan – betametason

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Betametason – örondroppar

Betametason – örondroppar

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Läkemedelsverket. Diprotit Produktresumé. Läkemedelsverket [www]. [updated 2021-06-02, cited 2025-12-17].

  2. Liu X, Li M, Smyth H, Zhang F. Otic drug delivery systems: formulation principles and recent developments. Drug Dev Ind Pharm. 2018;44(9):1395-1408.

  1. Läkemedelsverket. Diprotit Produktresumé. Läkemedelsverket [www]. [updated 2021-06-02, cited 2025-12-17].
  2. Liu X, Li M, Smyth H, Zhang F. Otic drug delivery systems: formulation principles and recent developments. Drug Dev Ind Pharm. 2018;44(9):1395-1408.
2 2
2 2

Betametason – systemiskt

Betametason – systemiskt

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. UK Teratology Information Service (UKTIS). USE OF SYSTEMIC CORTICOSTEROIDS IN PREGNANCY. UKTIS [www]. [updated 2023-07-01, cited 2025-12-17].

  2. Jølving LR, Nielsen J, Andersen ML, Friedman S, Nørgård BM. Adverse birth outcomes and early-life infections after in utero exposure to corticosteroids for inflammatory bowel disease: a Danish nationwide cohort study. BMC Med. 2023;21(1):140.

  3. Bay Bjørn AM, Ehrenstein V, Hundborg HH, Nohr EA, Sørensen HT, Nørgaard M. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Ther. 2014;21(2):73-80.

  4. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183(7):796-804.

  5. Xiao WL, Liu XY, Liu YS, Zhang DZ, Xue LF. The relationship between maternal corticosteroid use and orofacial clefts-a meta-analysis. Reprod Toxicol. 2017;69:99-105.

  6. Reprotox. Prednisolone. Micromedex [www]. [cited 2023-02-08].

  7. Hellgren K, Secher AE, Glintborg B, Rom AL, Gudbjornsson B, Michelsen B et al. Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis: a matched cohort study from Sweden and Denmark. Rheumatology (Oxford). 2022;61(9):3711-3722.

  8. Rikshandboken i barnhälsovård. Vägledning för vaccination med levande försvagade vaccin, av barn som under graviditeten eller vid amning exponerats för immunmodulerande läkemedel. Rikshandboken i barnhälsovård [www]. [updated 2022-09-26, cited 2025-12-17].

  9. Burton PJ, Waddell BJ. Dual function of 11beta-hydroxysteroid dehydrogenase in placenta: modulating placental glucocorticoid passage and local steroid action. Biol Reprod. 1999;60(2):234-40.

  10. Beitins IZ, Bayard F, Ances IG, Kowarski A, Migeon CJ. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr. 1972;81(5):936-45.

  11. Blanford AT, Murphy BE. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol. 1977;127(3):264-7.

  12. Briggs G, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 12th ed; 2021.

  1. UK Teratology Information Service (UKTIS). USE OF SYSTEMIC CORTICOSTEROIDS IN PREGNANCY. UKTIS [www]. [updated 2023-07-01, cited 2025-12-17].
  2. Jølving LR, Nielsen J, Andersen ML, Friedman S, Nørgård BM. Adverse birth outcomes and early-life infections after in utero exposure to corticosteroids for inflammatory bowel disease: a Danish nationwide cohort study. BMC Med. 2023;21(1):140.
  3. Bay Bjørn AM, Ehrenstein V, Hundborg HH, Nohr EA, Sørensen HT, Nørgaard M. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Ther. 2014;21(2):73-80.
  4. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183(7):796-804.
  5. Xiao WL, Liu XY, Liu YS, Zhang DZ, Xue LF. The relationship between maternal corticosteroid use and orofacial clefts-a meta-analysis. Reprod Toxicol. 2017;69:99-105.
  6. Reprotox. Prednisolone. Micromedex [www]. [cited 2023-02-08].
  7. Hellgren K, Secher AE, Glintborg B, Rom AL, Gudbjornsson B, Michelsen B et al. Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis: a matched cohort study from Sweden and Denmark. Rheumatology (Oxford). 2022;61(9):3711-3722.
  8. Rikshandboken i barnhälsovård. Vägledning för vaccination med levande försvagade vaccin, av barn som under graviditeten eller vid amning exponerats för immunmodulerande läkemedel. Rikshandboken i barnhälsovård [www]. [updated 2022-09-26, cited 2025-12-17].
  9. Burton PJ, Waddell BJ. Dual function of 11beta-hydroxysteroid dehydrogenase in placenta: modulating placental glucocorticoid passage and local steroid action. Biol Reprod. 1999;60(2):234-40.
  10. Beitins IZ, Bayard F, Ances IG, Kowarski A, Migeon CJ. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr. 1972;81(5):936-45.
  11. Blanford AT, Murphy BE. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol. 1977;127(3):264-7.
  12. Briggs G, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 12th ed; 2021.
2 2
2 2

Betametason – hudläkemedel

Betametason – hudläkemedel

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian J Dermatol. 2014;59(5):460-4.

  2. Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2015;10:CD007346.

  3. Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol. 2007;197(6):585e1-7; discussion 683-4, e1-7.

  4. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183(7):796-804.

  5. Edwards MJ, Agho K, Attia J, Diaz P, Hayes T, Illingworth A et al. Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Am J Med Genet 2003;120A:459-63.

  6. Mygind H, Thulstrup AM, Pedersen L, Larsen H. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancy. Acta Obstet Gynecol Scand 2002;81:234-9.

  7. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997;56:335-40.

  8. Skuladottir H, Wilcox AJ, Ma C, Lammer EJ, Rasmussen SA, Werler MM et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A Clin Mol Teratol. 2014;100(6):499-506.

  9. Läkemedelsverket. Betnovat Produkresumé. Läkemedelsverket [www]. [updated 2021-11-02, cited 2025-12-17].

  1. Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian J Dermatol. 2014;59(5):460-4.
  2. Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2015;10:CD007346.
  3. Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol. 2007;197(6):585e1-7; discussion 683-4, e1-7.
  4. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183(7):796-804.
  5. Edwards MJ, Agho K, Attia J, Diaz P, Hayes T, Illingworth A et al. Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Am J Med Genet 2003;120A:459-63.
  6. Mygind H, Thulstrup AM, Pedersen L, Larsen H. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancy. Acta Obstet Gynecol Scand 2002;81:234-9.
  7. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997;56:335-40.
  8. Skuladottir H, Wilcox AJ, Ma C, Lammer EJ, Rasmussen SA, Werler MM et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A Clin Mol Teratol. 2014;100(6):499-506.
  9. Läkemedelsverket. Betnovat Produkresumé. Läkemedelsverket [www]. [updated 2021-11-02, cited 2025-12-17].